Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA ne… Read more
Market Cap & Net Worth: Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (SHG:688221) has a market capitalization of $969.98 Million (CN¥7.12 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #9797 globally and #2066 in its home market, demonstrating a 0.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's stock price CN¥19.00 by its total outstanding shares 374578653 (374.58 Million).
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Market Cap History: 2020 to 2026
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's market capitalization history from 2020 to 2026. Data shows change from $982.75 Million to $969.98 Million (-8.09% CAGR).
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.85x
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's market cap is 3.85 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $982.75 Million | $46.62 Million | -$230.73 Million | 21.08x | N/A |
| 2021 | $949.05 Million | $40.50 Million | -$260.06 Million | 23.43x | N/A |
| 2022 | $881.15 Million | $84.74 Million | -$356.76 Million | 10.40x | N/A |
| 2023 | $506.43 Million | $114.25 Million | -$328.96 Million | 4.43x | N/A |
| 2024 | $498.26 Million | $129.47 Million | -$201.38 Million | 3.85x | N/A |
Competitor Companies of 688221 by Market Capitalization
Companies near Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Historical Marketcap From 2020 to 2026
Between 2020 and today, Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's market cap moved from $982.75 Million to $ 969.98 Million, with a yearly change of -8.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥969.98 Million | +5.26% |
| 2025 | CN¥921.48 Million | +84.94% |
| 2024 | CN¥498.26 Million | -1.61% |
| 2023 | CN¥506.43 Million | -42.53% |
| 2022 | CN¥881.15 Million | -7.15% |
| 2021 | CN¥949.05 Million | -3.43% |
| 2020 | CN¥982.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $969.98 Million USD |
| MoneyControl | $969.98 Million USD |
| MarketWatch | $969.98 Million USD |
| marketcap.company | $969.98 Million USD |
| Reuters | $969.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.